AstraZeneca PLC(AZN)Stock Performance & ReturnsNYSE
Returns, drawdowns and benchmark comparison
Peer Comparison
Relative scale, growth, and profitability vs sector peers
| Ticker | Market Cap | P/E Ratio | Revenue Growth | Net Margin | EPS | ROE | Debt/Equity | Dividend Yield | 52W High | 52W Low |
|---|---|---|---|---|---|---|---|---|---|---|
AZN | 261.82 B | 24.26x | 6.40% | 17.02% | $6.96 | 21.97% | 0.64x | 1.94% | $212.71 | $153.41 |
AZN.L | 19.57 T | 2445.35x | 6.40% | 17.02% | $5.16 | 21.97% | 0.64x | 0.03% | $15729.35 | $9891.35 |
HLN.L | 3.31 T | 2088.33x | 2.20% | 14.55% | $0.18 | 10.09% | 0.50x | 0.02% | $416.02 | $317.78 |
HIK.L | 341.99 B | 1251.52x | 4.20% | 11.32% | $1.32 | 15.41% | 0.77x | 0.05% | $1864.16 | $1186.46 |
Peer Valuation & Performance Analysis
Peer group analysis for AstraZeneca PLC (AZN) compared to its primary competitors (including AZN.L, HLN.L, HIK.L) reveals distinct metrics. AZN trades at a valuation discount relative to its competitors, with a P/E ratio of 24.3x versus the peer average of 1928.4x (representing a 99% discount). This discount might represent an undervalued entry opportunity or reflect specific risk factors the market is discounting. In terms of growth, AZN's revenue growth of 6.4% exceeds the peer average of 4.3%, highlighting its competitive strength and market share gains. Additionally, it boasts superior profitability with a net margin of 17.0% compared to the peer average of 14.3%, demonstrating strong cost controls and pricing power.
Peer Performance Rankings
Ranking comparison across key performance metrics
P/E Ratio (Lower is Better)
Revenue Growth
Net Profit Margin
Financial Rankings Summary
• AZN ranks #1 in P/E ratio, #1 in revenue growth, and #1 in profit margins
• Average ranking: #1 - 🎯 Top-tier fundamentals relative to peer group
• Rankings based on actual financial data from company reports
Historical Trading Data
Price and volume data with customizable timeframes
Showing 15 of 15 trading sessions from the last 15 days
| Date | Open | High | Low | Close | Volume | Daily Change |
|---|---|---|---|---|---|---|
| 2026-10-21 | $168.91 | $169.84 | $168.09 | $168.45 | 1,853,951 | -0.22% |
| 2026-10-20 | $166.77 | $169.24 | $166.66 | $168.82 | 4,592,300 | +2.97% |
| 2026-10-19 | $164.51 | $166.10 | $163.91 | $163.95 | 2,322,100 | -0.88% |
| 2026-10-16 | $166.97 | $167.18 | $164.37 | $165.41 | 3,460,900 | -0.76% |
| 2026-10-15 | $167.69 | $169.81 | $166.49 | $166.68 | 4,403,800 | +2.87% |
| 2026-10-14 | $158.71 | $162.71 | $158.31 | $162.03 | 3,333,500 | +3.99% |
| 2026-10-13 | $160.76 | $160.83 | $154.00 | $155.82 | 3,112,400 | -1.59% |
| 2026-10-12 | $159.44 | $159.44 | $157.60 | $158.33 | 2,855,600 | -0.55% |
| 2026-10-09 | $159.45 | $160.07 | $158.53 | $159.20 | 2,121,700 | +0.26% |
| 2026-10-08 | $159.80 | $160.05 | $156.72 | $158.78 | 3,488,700 | -0.84% |
| 2026-10-07 | $159.12 | $161.29 | $158.53 | $160.12 | 2,458,400 | +0.95% |
| 2026-10-06 | $159.80 | $159.96 | $156.26 | $158.61 | 2,050,200 | +1.33% |
| 2026-10-05 | $156.76 | $157.20 | $154.81 | $156.53 | 2,256,000 | -0.24% |
| 2026-10-02 | $158.46 | $158.80 | $156.41 | $156.90 | 3,035,400 | -0.51% |
| 2026-10-01 | $160.77 | $161.33 | $157.54 | $157.70 | 3,377,400 | -2.33% |
Explore More Analysis for AZN
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.